(PDF) Combining Bh3-Mimetics to Target Both BCL-2 and McL1

Combining Bh3-Mimetics to Target Both BCL-2 and McL1 Has Potent Activity in Pre-Clinical Models of Acute Myeloid Leukemia

Leukemia - United Kingdom

doi 10.1038/s41375-018-0261-3

Full Text

Abstract

Available in full text

Categories

Cancer Research

Date

September 10, 2018

Authors

Donia M. Moujalled

Giovanna Pomilio

Audrey Claperon

Francesca Rocchetti

Laurence Kraus-Berthier

Ensar Halilovic

Frédéric Colland

Andrew W. Roberts

Ana Leticia Maragno

Guillaume Lessene

Olivier Geneste

Publisher

Springer Science and Business Media LLC

Related search

The BCL-2 Protein Family, BH3-mimetics and Cancer Therapy

Cell Death and Differentiation

Molecular Biology

English

Primed for the Kill: Occupying BCL-2 to Target Death in Acute Myeloid Leukaemia

English

Superior Anti-Tumor Activity of the MDM2 Antagonist Idasanutlin and the BCL-2 Inhibitor Venetoclax in P53 Wild-Type Acute Myeloid Leukemia Models

Journal of Hematology and Oncology

Cancer Research

Molecular Biology

English

Inhibition of Flt3 and Pim Kinases by Ec-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia

Molecular Cancer Therapeutics

Cancer Research

English

BCL-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia

Cancer Research

Cancer Research

English

Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia

Multidisciplinary

English

Reply to ABCG2 Overexpression and Deoxyadenosine Analogue Activity in Acute Myeloid Leukemia

Cancer Research

English

Pin1 Inhibition Exerts Potent Activity Against Acute Myeloid Leukemia Through Blocking Multiple Cancer-Driving Pathways

Journal of Hematology and Oncology

Cancer Research

Molecular Biology

English

Mutated Ptpn11 Alters Leukemic Stem Cell Frequency and Reduces the Sensitivity of Acute Myeloid Leukemia Cells to McL1 Inhibition

Cancer Research

English